@article{14a2e99d8bf04430be05df9a18ddae47,
title = "Theory of Mind and social functioning among neuropsychiatric disorders: A transdiagnostic study",
abstract = "Social dysfunction is commonly present in neuropsychiatric disorders of schizophrenia (SZ) and Alzheimer's disease (AD). Theory of Mind (ToM) deficits have been linked to social dysfunction in disease-specific studies. Nevertheless, it remains unclear how ToM is related to social functioning across these disorders, and which factors contribute to this relationship. We investigated transdiagnostic associations between ToM and social functioning among SZ/AD patients and healthy controls, and explored to what extent these associations relate to information processing speed or facial emotion recognition capacity. A total of 163 participants were included (SZ: n=56, AD: n=50 and age-matched controls: n=57). Social functioning was assessed with the Social Functioning Scale (SFS) and the De Jong-Gierveld Loneliness Scale (LON). ToM was measured with the Hinting Task. Information processing speed was measured by the Digit Symbol Substitution Test (DSST) and facial emotion recognition capacity by the facial emotion recognition task (FERT). Case-control deficits in Hinting Task performance were larger in AD (rrb = -0.57) compared to SZ (rrb = -0.35). Poorer Hinting Task performance was transdiagnostically associated with the SFS (βHinting-Task = 1.20, p<0.01) and LON (βHinting-Task = -0.27, p<0.05). DSST, but not FERT, reduced the association between the SFS and Hinting Task performance, however the association remained significant (βHinting-Task = 0.95, p<0.05). DSST and FERT performances did not change the association between LON and Hinting Task performance. Taken together, ToM deficits are transdiagnostically associated with social dysfunction and this is partly related to reduced information processing speed.",
keywords = "Alzheimer's disease, Facial emotion recognition, Information processing speed, Schizophrenia, Social functioning, Theory of Mind",
author = "S. Braak and T. Su and W. Krudop and Pijnenburg, {Y. A.L.} and Reus, {L. M.} and {van der Wee}, N. and Bilderbeck, {A. C.} and Dawson, {G. R.} and {van Rossum}, {I. Winter} and Campos, {A. Vieira} and C. Arango and Saris, {I. M.J.} and Kas, {M. J.} and Penninx, {B. W.J.H.}",
note = "Funding Information: Dr Arango was supported by the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III, co-financed by ERDF Funds from the European Commission, “A way of making Europe”, CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundaci{\'o}n Familia Alonso and Fundaci{\'o}n Alicia Koplowitz. Funding Information: The PRISM project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115916. The PRISM2 project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101034377. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. This publication reflects only the author's views and neither the IMI 2JU nor EFPIA nor the European Commission are liable for any use that may be made of the information contained therein. The IMI 2JU had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. Funding Information: The PRISM project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115916. The PRISM2 project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101034377. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA. This publication reflects only the author's views and neither the IMI 2JU nor EFPIA nor the European Commission are liable for any use that may be made of the information contained therein. The IMI 2JU had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. Dr Arango was supported by the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III, co-financed by ERDF Funds from the European Commission, “A way of making Europe”, CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundaci{\'o}n Familia Alonso and Fundaci{\'o}n Alicia Koplowitz. None. Funding Information: Dr van der Wee was on advisory boards for Pfizer, Servier and Eli Lilly and received grants from the EU and the Netherlands Organisation for Health Research and Development. Publisher Copyright: {\textcopyright} 2022",
year = "2022",
month = nov,
doi = "https://doi.org/10.1016/j.euroneuro.2022.08.005",
language = "English",
volume = "64",
pages = "19--29",
journal = "European neuropsychopharmacology",
issn = "0924-977X",
publisher = "Elsevier",
}